EWTX Stock: Price, Earnings History and SEC Filings
Edgewise Therapeutics, Inc. (EWTX) last traded at $38.90, down 0.03% on the latest session and down 4.2% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.53 against an analyst estimate of $-0.48, a miss of 10.4%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
EWTX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $-0.53 | $-0.48 | -10.42% |
| Mar 2026 | May 7, 2026 | $-0.46 | $-0.50 | +8.00% |
| Dec 2025 | Feb 26, 2026 | $-0.47 | $-0.43 | -9.30% |
| Sep 2025 | Nov 6, 2025 | $-0.39 | $-0.40 | +2.50% |
EWTX beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
How EWTX reacts to earnings
Across its last 8 earnings releases, EWTX moved 2.4% on average the next session, in either direction. It rose after 1 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-06 | Before open | -1.27% |
| 2026-05-07 | Before open | -3.81% |
| 2026-02-26 | Before open | -1.53% |
| 2025-11-06 | Before open | -1.61% |
| 2025-08-07 | Before open | -4.18% |
| 2025-05-08 | Before open | +1.24% |
| 2025-03-03 | Before open | -2.45% |
| 2024-11-07 | Before open | -3.25% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
EWTX financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | – | -$168M | -$144M | – | $-1.63 |
| 2024 | – | -$134M | -$110M | – | $-1.45 |
| 2023 | – | -$100M | -$98M | – | $-1.57 |
| 2022 | – | -$68M | -$58M | – | $-1.26 |
| 2021 | – | -$43M | -$34M | – | $-1.14 |
| 2020 | – | -$17M | -$15M | – | $-23.17 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for EWTX
- 10-Q · Aug 6, 2026
- 8-K · Aug 6, 2026Results of operations, Financial statements and exhibits
- 8-K · Jul 13, 2026Acquisition or disposal completed, Regulation FD disclosure, Financial statements and exhibits
- 8-K · Jun 5, 2026Shareholder vote
- 8-K · Jun 1, 2026Material agreement, Financial statements and exhibits
- 8-K · May 7, 2026Results of operations, Financial statements and exhibits
- 10-Q · May 7, 2026
- DEF 14A · Apr 23, 2026
- 10-K · Feb 26, 2026
- 8-K · Feb 26, 2026Results of operations, Financial statements and exhibits
Insider filing activity
EWTX insiders filed 7 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
EWTX news
- Edgewise Therapeutics' Investors Focused on Upcoming Phase 3 Design for '7500 in Hypertrophic Cardiomyopathy, RBC SaysOct 27, 2026 · finance.yahoo.com
- William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates CoverageOct 21, 2026 · finance.yahoo.com
- Can Myqorzo's Expansion and Growing Adoption Drive CYTK's Growth?Oct 19, 2026 · finance.yahoo.com
About Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc. (EWTX) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.